Cardiff Oncology Inc
Cardiff Oncology Inc (CRDF) is a small, clinical-stage biotechnology company focused on developing oncology treatments. With a market capitalisation around $148 million, it is early-stage and carries the higher risk profile typical of companies without commercial revenues. Investors should know Cardiff is research-driven: value depends heavily on clinical trial outcomes, regulatory progress and partnerships rather than current sales. News flow — trial readouts, investigator updates and licensing deals — can move the share price significantly. Financially, expect periodic funding needs through equity raises or collaborations, which can dilute existing holders. For those considering exposure, treat CRDF as a speculative, long-horizon position and weigh the potential upside from successful development against the significant chance of setbacks. This summary is educational only and not personal investment advice; consult a qualified adviser about suitability for your circumstances.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Cardiff Oncology's stock with a target price of $11.33, indicating strong growth potential.
Financial Health
Cardiff Oncology is generating modest revenue and cash flow, but overall financial stability is unclear.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CRDF
Alternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: October 13, 2025
Explore BasketFDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketCancer Drug Safety: Could Warnings Create Opportunities?
The FDA's decision to add its strongest safety warning to a key cancer therapy from Johnson & Johnson and Legend Biotech underscores the inherent risks of powerful new treatments. This regulatory action could boost companies developing safer alternative cancer therapies, creating a new investment opportunity in the biotech sector.
Published: October 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Catalysts to watch
Clinical readouts, regulatory updates and collaboration news can shift valuation quickly — though outcomes are uncertain and may increase volatility.
Development risk
As a research-led company, progress depends on trials and approvals; setbacks are common and can materially impact the share price.
Funding and partners
Partnerships or financing rounds can extend runway and validate programmes, but funding may dilute existing shareholders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
